iNeuro Secures Third Place at Takeda China Innovation Challenge with Multimodal LGS EEG AI Screening Platform

Jul 24, 2024 16:31 CST Updated 16:31

iNEURO

Provider of Comprehensive Brain Science Medical Solutions

July 23,The 3rd Takeda China Innovation ChallengeSuccessfully concluded in Shanghai, marking another innovative event in the healthcare field, this competition served as an important milestone for Takeda's open innovation incubation platform, TakedaSpark. It brought together digital health innovators from across China to jointly explore a new future for the healthcare sector.

In this competition, iNEURO stood out with its cutting-edge "Multimodal LGS EEG Intelligent Screening Platform"The project stood out among numerous entries, shining brightly and winning third place in this challenge. This not only highlights iNEURO's profound expertise and innovative capabilities in the digital healthcare field but also marks that its technological achievements have received high recognition from industry authorities."

Third Place in the Second Takeda China Innovation Challenge

2024.07.24

Multimodal LGS EEG Intelligent Screening Platform

iNEURO's "Multimodal LGS EEG Intelligent Screening Platform", is a model of deep integration of technology and healthcare. The platform combines advanced artificial intelligence algorithms with multimodal data fusion technology to precisely analyze EEG signals and integrate them with other physiological indicators, specifically targetingLGS, a rare and severe pediatric epileptic encephalopathy`, aiming to improve diagnostic efficiency and accuracy, has opened a new path of hope for the early diagnosis and treatment of young patients.`

As an important innovation platform in the healthcare field, Takeda China Innovation Challenge continues to explore and support innovative projects with commercial potential. Through TakedaSpark, an open innovation platform, it builds a bridge of cooperation between innovative enterprises and Takeda Pharmaceuticals, jointly promoting the innovative development of the healthcare industry.

The award won by iNEURO this time is yet another fruitful result of the in-depth cooperation between the two parties, accelerating the transformation of scientific and technological achievements and jointly promoting the innovative development of the healthcare industry.

Dr. Dai Shenxi, Founder and Chief Scientist of iNEURO"This honor is an affirmation of our team's relentless efforts and, more importantly, an encouragement for future exploration. iNEURO will continue to deeply cultivate the digital healthcare field, collaborate with industry partners like Takeda Pharmaceuticals, explore more possibilities together, and contribute greater strength to the cause of human health."

In the future, iNEURO will actively respond to China's health strategy,Increase technology investment,Continuously deepen the research and innovation in the field of brain health, and strengthen cooperation with Takeda Pharmaceutical,Deep IntegrationArtificial Intelligence and Precision Medicine，CommonPromote the Popularization of Early Screening and Diagnosis in the Field of Brain Diseases/Brain Health and Advance Scientific Research, providing patients with precise and efficient diagnosis and treatment plans, leading the new trend of healthy medical care, and creating a healthy future together.